Understanding the FDA’s Rejection of SYD-101: Navigating the Challenges in Pediatric Myopia Treatment

Introduction

Myopia, or nearsightedness, is a growing public health challenge worldwide, especially among children. This refractive error causes distant objects to appear blurry, often worsening progressively through childhood and adolescence. Left unchecked, high myopia increases the risk of serious eye complications including retinal detachment, glaucoma, and macular degeneration later in life. Given the increasing prevalence of pediatric myopia, effective treatments to slow its progression are of paramount importance. Recently, the U.S. Food and Drug Administration (FDA) denied approval for SYD-101, a low-dose atropine eye drop developed by Sydnexis and designed to slow myopic progression in children aged 3 to 14. This decision, despite SYD-101’s regulatory approval in Europe and positive phase III trial results, sparks critical reflection on drug development challenges and regulatory expectations in pediatric ophthalmology.

Background and Clinical Context